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BACKGROUND: Women with diabetes have higher low-
density lipoprotein (LDL) levels than men, resulting in
apparent disparities between genders on quality indi-
cators tied to LDL thresholds.
OBJECTIVE: To investigate whether gender disparities
persist when accounting for clinical action with statins
or cardiovascular risk.
DESIGN: Retrospective cohort study.
PARTICIPANTS: Veterans Health Administration
patients (21,780 women and 646,429 men) aged 50–
75 with diabetes.
MAIN MEASURES: Threshold measure: LDL < 100 mg/
dL; clinical action measure: LDL < 100 mg/dL; or LDL ≥
100 mg/dL and the patient was prescribed a moderate
or high-dose statin at the time of the test; or LDL ≥
100 mg/dL and the patient received other appropriate
clinical action within 90 days; adherence: continuous
multiple interval measure of gaps in dispensed medica-
tion (CMG).
KEY RESULTS:Women were much less likely to have
LDL < 100 mg/dL than were men (55 % vs. 68 %).
This disparity narrowed from 13 % to 6 % for
passing the clinical action measure (79 % vs.
85 %). These gender differences persisted among
those with ischemic heart disease (IHD). Women
had a lower odds of passing the clinical action
measure (odds ratio 0.68, 95 % confidence interval
0.66–0.71). Among those with IHD, the gender gap
increased with age. Differences in pass rates were
explained by women’s higher LDL levels, but not by
their slightly worse adherence (3 % higher CMG).
CONCLUSIONS: Women and men veterans receive
more similar quality of care for lipids in diabetes
than previously indicated. Less reassuringly, the
remaining gender differences appear to be as com-
mon in women at high cardiovascular risk as in
those at low risk. Rather than focus on simply
improving LDL levels in all women with diabetes,
future efforts should ensure that patients with high
cardiovascular risk are appropriately treated with
statins when clinically indicated, feasible, and con-
cordant with patient preferences.
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INTRODUCTION
Large gender differences in achievement of target low-
density lipoprotein (LDL) levels are reported consistently in
diabetic populations.1–7 However, there are relatively small
differences by gender in initiation and provision of lipid
lowering treatment.1,2,8 It is not yet clear whether these
observations reflect less aggressive treatment intensification
in women on the part of providers, poorer adherence to
treatment on the part of women, or some combination of the
two. Furthermore, if women are treated less aggressively
than men, it is unknown whether this appropriately reflects
their lower overall cardiovascular risk once other risk
factors are taken into account.
Nevertheless, the obvious consequence of the higher
LDL levels seen in diabetic women is that existing LDL <
100 mg/dl quality measures are attained less frequently in
women than in men. For example, among patients using
Department of Veterans Affairs (VA) medical facilities in
fiscal year (FY) 2011, the gender difference was 14 % for
those with diabetes, and 16 % for those with ischemic heart
disease (IHD), suggesting significant quality gaps between
women and men.9 This difference occurs even as the VA
exceeds the private sector on many measures of perfor-
mance for both gender-specific and gender-neutral
care,5,10,11 and provides comparable quality of care to
women and men veterans by most measures.12 The utility of
this LDL target quality measure has come under serious
scrutiny, however.13 Recent literature suggests that the
method of treatment for hyperlipidemia may be as or more
important than attainment of an LDL target,14,15 and
S529
professional society treatment guidelines now credit use of
a statin in addition to achievement of low LDL levels.16–18
In 2012, in light of the shifting paradigm and evolving
definition of high-quality care, the VA adopted a new
quality measure for lipid management in diabetes that
was developed by a workgroup of clinical and measure-
ment experts and accounts for clinical action in addition
to LDL levels (personal communication, Kerr 2011).
Development of this measure followed similar work
developing a clinical action performance measure for
blood pressure management in the VA.19 Including the
focus on clinical action deemphasizes target attainment
and acknowledges the effectiveness of appropriate
therapy—in this case, use of statins in diabetes.
In this study, we hypothesize that taking appropriate
clinical action for lipid management into account will
reduce estimates of gender disparities based on LDL
thresholds alone among veterans with diabetes. If providers
are appropriately using cardiovascular risk to tailor treat-
ment, we also expect to see further narrowing of any gender
differences among those with increased levels of cardiovas-
cular risk, such as those patients with IHD and diabetes or
with increasing age. Finally, we hypothesize that any
persistent disparities with use of the clinical action measure
will be explained in part by worse adherence among
women.
METHODS
Subjects and Study Design
We used data from the VA Corporate Data Warehouse
(CDW), a national repository comprising data from
multiple VA clinical and administrative systems. Data
included information on outpatient encounters; vital
signs; ICD-9 diagnoses; prescription medication fills,
doses, quantities and days’ supply; and laboratory
values. We conducted a retrospective cohort study of
data from women and men aged 50–75 with diabetes
active in primary care at a VA medical center (VAMC)
or community-based outpatient clinic (CBOC) during
July 1, 2010 to June 30, 2011. We identified patients
with diabetes on the basis of two outpatient visits with
ICD-9 codes for diabetes, or a total of ≥ 31 days of
prescription diabetes medications filled in the 24 months
prior to the study period. For the patient to be included
in the study, one of these visits or fills needed to be in
the 12 months prior to the start of the study period.
Active patients were defined as those with ≥ two
primary care clinic visits in the 24 months prior to the
study period and ≥ one primary care clinic visit during
the study period. Patients were assigned to a facility
based upon the location of most primary care visits
during the study period. We found 881 unique facilities.
We excluded those with ICD-9 codes for dialysis;
pregnancy; liver, esophageal, or pancreatic cancer; death
during the study period; or with limited life expectancy
recorded in response to clinical reminders in the
electronic medical record. The VA Ann Arbor Health-
care System’s Subcommittee on Human Studies ap-
proved this study.
Patient Data
Body mass index (BMI) was calculated from weight and
height. We reported mean blood pressure and LDL and
most recent hemoglobin A1C from the year prior to the
study period. Comorbidities were identified using ICD-9-
CM codes.20 We classified certain conditions as concordant,
meaning that treatments for these conditions are generally
related to and/or overlap with diabetes care.21,22 These
included hypertension, hyperlipidemia, obesity, heart fail-
ure, ischemic heart disease, peripheral vascular disease,
renal disease, and cerebrovascular disease. All other
conditions were considered non-concordant.
Clinical Action Quality Measure
The clinical action measure23 is intended to account for
LDL target achievement as well as processes that are
associated with positive results irrespective of intermediate
outcomes.14,18,24 The measure was considered met in those
instances where: index LDL < 100 mg/dL; or LDL ≥
100 mg/dL and the patient was prescribed a moderate-dose
or high-dose statin at the time of the test or within 90 days;
or index LDL ≥ 100 mg/dL and the patient received other
appropriate clinical action within 90 days. The last LDL
value of the study period was the index LDL. Those with no
LDL test recorded but who were prescribed a moderate or
high dose statin passed the measure on the basis of the
prescription. “Other appropriate clinical action” included
starting, changing, or intensifying low-dose statin therapy,
or finding an LDL < 100 mg/dL upon repeat testing. The
measure limits credit for lipid-lowering medication use to
statins only; other lipid-lowering medications are not
definitively associated with reduced cardiovascular disease
(CVD) events. The measure also focuses on statins at a
moderate dose, which have strong evidence for cardio-
vascular event reduction and total mortality.25–30 Mod-
erate-dose statins are those that produce a 30–40 %
decrease in LDL levels. Statins at low dose appear to be
of limited benefit in reducing CVD risk, but because
many patients may be unable to tolerate moderate dose
statins, the measure credits starting a low dose statin as
evidence of a reasonable provider attempt to improve
lipid control. The definitions of low-dose, moderate-dose
and high-dose statins are based on the relative potency
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of each statin in lowering LDL levels and are presented
in the Appendix.
Statistical Analysis
We calculated the proportions of women and men who met
the LDL < 100 mg/dL threshold measure and the clinical
action measure, both for the entire identified population and
for those with IHD. Using multilevel logistic regression
models controlling for age and with facility as a random
effect, we examined the association of gender with the
likelihood of passing the LDL < 100 mg/dL threshold
measure. We used sequential models to control for
utilization factors, including the number of primary care
visits and type of facility (VAMC or CBOC). We then
further adjusted for indicators of cardiovascular risk:
presence of IHD and BMI. These analyses were repeated
using the clinical action measure as the outcome variable.
We tested interactions between gender and both age and
IHD for the clinical action measure. We compared the
distribution of statin dose levels and examined LDL control
by statin dose in women and men.
In order to explore the effect of adherence to statins in
women and men, we used automated VA pharmacy data to
calculate the continuous, multiple interval measure of gaps
in therapy (CMG).31,32 The CMG has been shown to be a
reliable estimate of patient adherence33 and is defined as:
total number of days without medication/total number of
days the patient should have been taking medication,
expressed as a percentage. The larger the percent, the larger
the refill gaps and presumed worse adherence. We calcu-
lated the CMG based on prescription fills over the
12 months preceding the index LDL to account for
medication stockpiling from previous prescriptions. Medi-
cations which were not filled for ≥ 180 days were
considered discontinued rather than counted as missing
medication supply. We examined whether controlling for
adherence in the full model would change the association
between gender and having an LDL < 100 mg/dL.
RESULTS
The study included 21,780women and 646,429men (Table 1).
While A1C and blood pressure levels were similar between
women and men, women were younger (59.6 years vs.
63.9 years), had a higher BMI (34.2±7.2 kg/m2 vs. 32.6±
6.3 kg/m2), higher mean LDL level (102±34 mg/dL vs. 89±
29 mg/dL), and more non-concordant conditions. Women had
a lower prevalence of IHD (16 % vs. 23 %), were less likely
than men to be on either a moderate or a high dose statin (52%
vs. 57%) and were less likely to be seen in a community-based
outpatient center (CBOC).
Women were less likely than their male counterparts to meet
either the LDL threshold measure or the clinical action measure
(Table 2). Fifty-five percent of women and 68 % of men met the
LDL threshold measure (difference=13 %). Among those with
IHD, women were still less likely than men to meet the LDL
threshold measure (67 % vs. 81 %, difference=14 %). Women
were also less likely to meet the clinical action measure,
although the difference was smaller (79 % vs. 85 %,
difference=6 %). Among those with IHD, the gender difference
remained (84 % vs. 89 %, difference=5 %).
The gender difference in meeting the clinical action
measure was mostly explained by the lower rates of LDL
target achievement among women, as clinical action was very
similar in women and men with an LDL ≥ 100 mg/dL.
Specifically, of those with an LDL above threshold, a similar
proportion of women and men were on a moderate or high
dose statin either at the time of LDL, within 90 days of the
LDL, or in the absence of an LDL test (48 % vs. 50 %). In
addition, equal proportions of women and men with
LDL ≥ 100 mg/dL had a low-dose statin added or changed
(3%), had a dose increase (0.2 %) or had an LDL < 100mg/dL
on repeat testing (0.3 %).






Age (yrs) 59.6 (6.1) 63.9 (6.1) < 0.0001
A1C (%)† 7.3 (1.6) 7.3 (1.4) < 0.0001
BMI (mg/kg2)† 34.2 (7.2) 32.6 (6.3) < 0.0001
Mean SBP (mmHg) ‡ 132 (14) 132 (14) 0.27
Mean DBP (mmHg) ‡ 74 (9) 75 (9) < 0.0001
Mean LDL (mg/dl)‡ 102 (34) 89 (29) < 0.0001
Comorbidities (no.)§ 4.5 (2.2) 4.3 (2.1) < 0.0001
Non-concordant
conditions (no.)║













39 49 < 0.0001
A1C hemoglobin A1C, BMI body mass index, SBP systolic blood
pressure, DBP diastolic blood pressure, LDL low-density lipoprotein
*Values are mean (SD) unless otherwise indicated. †Mean value in
year prior to study year. ‡Most recent value from year prior to
study year. §Comorbidities were identified on the basis of ICD-9
codes listed in the two years prior to the study year. kConcordant
conditions included those whose treatment is generally related to,
or overlaps with, diabetes care and include hypertension,
hyperlipidemia, obesity, heart failure, ischemic heart disease,
peripheral vascular disease, renal disease, and cerebrovascular
disease. All others are considered non-concordant. Based on the
statin dose at start of study year
¶
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In multilevel models, we found that adjustment for age,
utilization factors, and cardiovascular risk explained some
of the gender difference in meeting the LDL threshold
measure, but not in meeting the clinical action measure
(Table 3). While the odds ratio (OR) for women of meeting
the LDL threshold measure increased from 0.51 [95 %
confidence interval (CI) 0.49–0.53] when adjusting for age
and facility alone to 0.61 (95 % CI 0.59–0.63) in the fully
specified model, the estimate was essentially unchanged for
the clinical action measure: 0.68 (95 % CI 0.66–0.71) with
adjustment for age and facility alone, and 0.67 (95 % CI
0.65–0.70) in the fully specified model. Increasing age, care
at a VAMC (vs. a CBOC), number of primary care
practitioner (PCP) visits, and presence of IHD were all
positively associated with meeting the clinical action
measure, even though adjustment for them did not lead to
a change in the odds that women met the measure.
In addition to adjusting for average age, we examined
whether the difference between women and men in meeting
the clinical action measure decreased with increasing
cardiovascular risk—either advancing age or IHD (Fig. 1).
While increasing age and IHD were each positively
associated with passing the measure, the effects of each
were weaker among women (P for both interactions
< 0.001). Among both women and men with IHD,
increasing age was associated with decreased rates of
meeting the clinical action measure. However, the gender
gap actually widened with age in this high-risk group.
The distribution of statin dose levels between women and
men was similar (Table 4). At every dose level, however,
women had a 12 mg/dL higher mean LDL value than did
men. The CMG (i.e. the mean percent of days without
medication) among women was 19 %; the mean in men was
16 % (mean difference=3 %). Adjusting for adherence only
slightly increased the estimate for the odds of a woman
passing the LDL < 100 measure (0.65, 95 % CI 0.62–0.67).
DISCUSSION
We found that accounting for appropriate clinical action in
addition to achievement of LDL threshold levels decreased
gender disparities in appropriate lipid management for
diabetes from 13 % to 6 %. Among high-risk individuals
with both diabetes and IHD, treatment was better for both


























84 89 5 < 0.0001
LDL low-density lipoprotein, IHD ischemic heart disease
*Clinical action measure defined as: LDL < 100 mg/dL; or LDL ≥
100 mg/dL and the patient was prescribed a moderate or high-dose
statin at the time of the test; or index LDL ≥ 100 mg/dL and the
patient received other appropriate clinical action within 90 days.
Those with no LDL test recorded, but who were prescribed a
moderate or high dose statin, also passed the measure on the basis
of the prescription. †IHD = ischemic heart disease
Table 3. Adjusted Odds Ratios for Passing Lipid Management










0.60 (0.58,0.62) 0.64 (0.62,0.66)
Age+facility+number of primary
care visits+type of facility+
IHD§+BMI║
0.61 (0.59,0.63) 0.67 (0.65,0.70)
LDL low-density lipoprotein, IHD ischemic heart disease, BMI body
mass index
*Odds ratios and 95 % confidence intervals †Clinical action measure
defined as: LDL < 100 mg/dL; or LDL ≥ 100 mg/dL and the patient
was prescribed a moderate or high-dose statin at the time of the test;
or index LDL ≥ 100 mg/dL and the patient received other appropriate
clinical action within 90 days. Those with no LDL test recorded, but
who were prescribed a moderate or high dose statin, also passed the
measure on the basis of the prescription. ‡VA medical center or
CBOC-community-based outpatient clinic. §IHD-ischemic heart dis-
ease. ║BMI – body-mass index (kg/m2)
Figure 1. Effects of age and ischemic heart disease on likelihood of
passing clinical action measure for lipid management in diabetes,
by gender.
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women and men overall, but the gender gaps did not
disappear. For those patients with LDL levels above
threshold, clinical action for women and men was similar.
Therefore, the persistent difference in the quality of lipid
management was driven by women’s higher LDL levels at
every statin dose level, including among those not on any
statin. We did not find that the slightly worse adherence to
statins among women fully explained these higher LDL
levels. Older women and women with IHD were not treated
as aggressively as their male counterparts.
The large difference in LDL levels that we report is
similar in magnitude to those reported in other studies
among diabetic populations both within and outside of the
VA.1–5,7, 34 However, the relevance of LDL levels alone as
a measure of quality has been questioned, with increasing
attention paid to appropriate method of treatment.13 In this
study, we found that, among women and men aged 50–75
with diabetes who do not meet LDL targets, provision of
statin therapy is very similar. In a previous study using data
from the VA Diabetes Epidemiology Cohorts,8 we noted
major lipid treatment disparities among younger veterans
with diabetes. Statins are contraindicated in pregnant or
breastfeeding women, so such a difference may reflect
appropriate clinical decision-making. However, that study
found only small differences in provision of lipid-lowering
therapy and initiation of statins among older veterans,
consistent with our current results. Studies in non-VA
populations have reported similarly small gender differ-
ences in provision of lipid-lowering therapy among older
adults.1,2,35 The present study extends this literature by
applying up-to-date concepts of quality of care for lipid
management that account for both LDL target achievement
and appropriate clinical action. In addition, we focus on
statins (the only lipid-lowering medication definitively tied
to decreased cardiovascular risk). Recent quality reporting
from the VA that applies the clinical action measure found
similar results to ours.9 We confirm that report’s findings in
a large, national population and explore the effect of
multiple indicators of cardiovascular risk as well as
adherence on gender differences in treatment.
It is noteworthy that LDL levels in women are higher without
statin therapy, and remain significantly higher than those in men
in the face of similar provider action and statin doses. The
higher LDL levels among women on treatment may reflect
higher starting levels before treatment, with providers being less
likely to treat women to target due to their own beliefs about
lower CVD risk inwomen,36, 37 patient preferences38–40 or drug
intolerance.41 Higher LDL levelsmay be acceptable if moderate
dose statin exposure, rather than LDL target achievement alone,
is ultimately a goal of treatment. If women’s higher LDL levels
reflect worse adherence, however, the lower degree of statin
exposure would be of concern. We found that gender differ-
ences in statin adherence were slight and did not explain the
higher LDL levels. We found a degree of difference in statin
adherence that is consistent with other studies,42 and it suggests
that adherence to statins is not a greater problem for women
than men in VA.
It is of concern, however, that both age and the presence of
IHD had a lesser effect on pass rates among women than men.
We also found that among those with IHD, the gender gap
widenedwith increasing age. Greater age and IHD are associated
with much higher 10-year risk of CVD in both genders. Statin
therapy is similarly effective in women and men, for both
primary and secondary prevention,43–45 and women should not
receive a different level of treatment intensity than men.
However, as for patients with diabetes as a whole, the reasons
for the gender gap in particularly high-risk individuals are
unclear and could lie at either the provider or the patient level.
Future research and quality improvement efforts should focus on
improving lipid management for these high-risk patients.
Our study has several strengths. It examines a national
population with large numbers of women, and we were able to
adjust for multiple confounders. It is also the first study of
which we are aware that applies the newest understandings of
quality of care for lipid management in diabetes to an
examination of gender disparities. However, our study also
has several limitations. The VA often outperforms non-VA
settings in meeting quality indicators, and differences in the
quality of care between women and men might be smaller than
those in the general population.10,11 Although we used a one-
year lookback period to assess adherence, the CMG likely does
not fully account for medication stockpiling, especially among
those who receive automated mail-order prescriptions. Howev-
er, our finding of only a small gender difference in statin
adherence is consistent with other studies. There are some
limitations to CDW data that could affect the validity of
measurement of performance on the clinical action measure.
For example, we were not able to capture testing or
prescriptions provided from outside of the VA system.
However, as the measure can be passed in multiple ways, the
likelihood of misclassifying an outcome is reduced. In addition,
women are more likely to use non-VA care than are men, so that













No statin 33 105 (38) 30 92 (32)
Low-dose 8 96 (34) 8 84 (28)
Moderate-dose 32 92 (33) 34 80 (28)
High-dose 27 95 (37) 29 83 (31)
*Based on the statin dose at the time of index LDL. †Percents do not
total to 100 due to rounding. ‡Pearson’s chi square testing the equality
of groups has a p value of < 0.0001.
§Mean difference of LDL within each statin dose was significantly
different by gender, with a p value < 0.0001
*Based on the statin dose at the time of index LDL. †Percents do not total
to 100 due to rounding. ‡Pearson’s chi square testing the equality f
groups has a P value of < 0.0001. §Mean differenc of LDL within each
statin do e was significantly different by gender, with a P value < 0.0001
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accounting for statin prescriptions outside of VA would likely
decrease our estimates of gender disparities even further.
Finally, we were not able to gather information on patient
preferences or statin side effects from our administrative data.
There is a paucity of data on these issues with respect to women
and statins. Some studies have found that women’s perception
of CVD risk is inaccurately low,46 and that they prioritize
cholesterol screening below gender-specific screening.47,48
With regard to side effects, one large observational study found
that women were less likely than men to develop serious
myopathy.49 However, some have argued that, in general, the
quality of data on differences in statin side effects by gender is
poor, as meta-analyses of safety data do not disaggregate for
women and do not explore gender-specific concerns, such as
breast cancer and pregnancy complications.50 Gender differ-
ences in preferences or side effects may explain some differ-
ences in treatment approach, however, and should be explored
in future studies.
Our results have important implications for policy,
practice and research. Significant resources have been
directed towards lowering LDL levels in women in VA,
based on large and persistent gender disparities in
meeting the LDL threshold measure. However, our use
of a clinical action measure suggests that the actual
quality of care for lipids in diabetic women and men,
while not equivalent, is more similar than previously
realized. Rather than focus on improving LDL levels in
all women with diabetes, future efforts should ensure that
patients with high cardiovascular risk are appropriately
treated with statins when clinically indicated, feasible,
and concordant with patient preferences.
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APPENDIX







atorvastatin < 10 ≥ 10 to < 40 ≥ 40
fluvastatin < 80 ≥ 80 –
lovastatin < 40 ≥ 40 –
pravastatin < 40 ≥ 40 –
rosuvastatin < 5 ≥ 5 to < 10 ≥ 10
simvastatin < 20 ≥ 20 to ≤ 40 > 40
Moderate dose statins are those that produce a 30–40 % reduction in
LDL51–54
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